Transcatheter Technologies is further expanding its product platform to include an endovascular aortic repair (EVAR) device: Tumbao
A thoracic or abdominal aortic aneurysm is a dilatation of the aortic vessel that occurs in 2–8% of patients older than 50 years. The dilatation presents none or few symptoms until rupture. In patients suffering a ruptured aortic aneurysm, the mortality is up to 80%. The most common methods of aortic repair are traditional open surgery and EVAR. In the surgical procedure, the wall of the aneurysm is replaced with a synthetic graft. In the EVAR procedure, a stent graft is inserted percutaneously through the femoral artery into the aneurysm. Unlike surgical aortic repair, recovery after EVAR is typically very fast.
The unique feature of the Transcatheter Technologies platform allows for precision-controlled expansion and anchoring of self-expanding Nitinol stents for the treatment of complex aortic aneurysm. With this proprietary system a stent can be repositioned—or even retrieved—if needed.
“We are expanding our platform technology to comprise not only Trinity TAVI for the treatment of aortic stenosis and Tresillo TMVI for the treatment of mitral valve insufficiency, but also a unique system, Tumbao, for endovascular aortic repair. Tumbao is designed to make aortic stenting more precise and safer,” said Wolfgang Goetz, chief executive officer. “This coated endovascular stent allows for precise positioning and anchoring, thus making the treatment of more complex aortic disorders possible.”
“Additionally, a short version of Tumbao can seal endoleaks between an existing aortic stent and the native aortic wall (endovascular aortic sealing),” said Goetz.
